Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 4, 2025
Context: The Company entered into a Securities Purchase Agreement for a private placement of ordinary shares to a single investor.
Key Financial Metrics
Capital Raise Details:
- Shares Issued: 333,334 ordinary shares
- Price Per Share: $1.50
- Gross Proceeds: Approximately $0.5 million (before offering expenses)
- Use of Proceeds: General corporate purposes and working capital
Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity ratios. Proceeds will be accounted for as shareholders' equity.
Material Changes
This filing reports a discrete capital event rather than a comparative period financial update. The material change is the agreement to issue new equity, which will increase the Company's share count and cash position upon closing.
Guidance, Outlook, and Risks
Closing Conditions: The Offering is expected to close on September 8, 2025, subject to customary conditions. If conditions are not satisfied, the Offering may not close.
Registration Obligations: The Company agreed to file a registration statement (Form F-3 or F-1) for resale of the shares within 60 business days of closing and use commercially reasonable efforts to have it declared effective within 90 calendar days.
Risks and Contingencies:
- The transaction relies on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Regulation D.
- Forward-looking statements regarding the closing date are not guaranteed.
- The Purchaser is represented as an accredited investor or qualified institutional buyer.
Investor Verification Checklist
- Confirm the actual closing date of the Offering (expected September 8, 2025).
- Verify the final number of shares issued and total net proceeds after deducting offering expenses.
- Monitor the filing of the resale registration statement (Form F-3 or F-1) within 60 business days of closing.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and conditions.